Investors & Media
News Releases
-
Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more -
Ryvu Therapeutics at BIO-Europe Spring
Read more -
Ryvu Therapeutics reports financial results for 2020
Read more -
Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition
Read more -
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting
Read more -
Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
Read more -
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Read more -
Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors
Read more -
"Dream with Ryvu" - a corporate movie by Ryvu Therapeutics
Read more -
Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry
Read more -
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read more -
Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski
Read more -
Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board
Read more -
Ryvu Therapeutics Reports Q3 2020 Financial Results
Read more -
Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference
Read more -
Ryvu Therapeutics at BIO-Europe 2020
Read more -
Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)
Read more -
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more -
Ryvu Therapeutics Reports 2020 Half-Year Financial Results
Read more -
Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Read more -
Ryvu Therapeutics raised over USD 36 million from its share issue
Read more -
The share issue price in Ryvu Therapeutics public offering set at PLN 60
Read more -
Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.
Read more -
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Read more -
Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy
Read more -
NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing
Read more -
Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs
Read more -
Ryvu Therapeutics at BIO Digital 2020
Read more -
Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Read more -
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II
Read more -
Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress
Read more -
Galapagos and Ryvu announce research collaboration
Read more -
Ryvu Therapeutics Reports Annual 2019 Financial Results
Read more -
Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference
Read more -
Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia
Read more -
Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more -
Ryvu Therapeutics at BIO-Europe Spring 2020
Read more -
Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference
Read more -
Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept
Read more -
Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors
Read more -
Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules
Read more -
Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read more -
Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read more -
Ryvu Therapeutics to Present at BIO-Europe 2019
Read more -
Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read more -
Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read more -
Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read more -
Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read more -
Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read more -
Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read more -
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read more -
Selvita to Present at Upcoming Conferences in September
Read more -
Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress
Read more -
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Read more -
Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting
Read more -
Selvita to present at the 2019 HCW Global Life Sciences Conference in London
Read more -
Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies
Read more -
Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Read more -
Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting
Read more -
Selvita to Present at Biotech Showcase 2019 in San Francisco
Read more -
Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting
Read more -
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read more -
Selvita to present new data from its oncology programs at the upcoming SITC 2018
Read more -
Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice
Read more -
Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry
Read more -
Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit
Read more -
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia
Read more -
Selvita publishes research results on SEL24 in Oncotarget
Read more -
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018
Read more -
Selvita Announces Successful Completion of $41 M Book Building
Read more -
FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read more -
Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read more -
Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more -
Selvita and Menarini present together at the European Business Development Conference
Read more -
Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read more -
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read more -
Selvita presents at 18th Drug Discovery Summit in Berlin
Read more -
Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read more -
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read more -
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more -
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017
Read more -
Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry
Read more -
Selvita to present at Biotech Showcase 2017 in San Francisco
Read more -
Selvita presents posters at 2016 EORTC-NCI-AACR Symposium
Read more -
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more -
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more -
Epidarex Capital Creates Nodthera Limite
Read more -
Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory
Read more -
Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016
Read more -
Selvita wins the European Rising Star Award
Read more -
The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition
Read more -
Merck and Selvita Announce Drug Discovery Collaboration
Read more -
Selvita launches new company – bioinformatics and personalized medicine focused Ardigen
Read more -
H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration
Read more -
Selvita receives the Economic Award of the President of Poland
Read more -
Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor
Read more -
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence
Read more -
Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014
Read more -
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more
-
Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read more -
Ryvu Therapeutics at BIO-Europe Spring
Read more -
Ryvu Therapeutics reports financial results for 2020
Read more -
Ryvu Therapeutics awarded in the Stock Exchange Company of the Year competition
Read more -
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2021 Virtual Annual Meeting
Read more -
Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR
Read more -
Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland
Read more -
Ryvu Therapeutics has submitted a new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors
Read more
-
"Dream with Ryvu" - a corporate movie by Ryvu Therapeutics
Read more -
Ryvu Therapeutics publishes MNK1/2 kinase inhibitors research paper in the European Journal of Medicinal Chemistry
Read more -
Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting
Read more -
Solebury Trout Talks Podcast: Interview with Pawel Przewiezlikowski
Read more -
Ryvu Therapeutics Appoints Kamil Sitarz as Chief Operating Officer and Member of the Management Board
Read more -
Ryvu Therapeutics Reports Q3 2020 Financial Results
Read more -
Ryvu Therapeutics at Jefferies Virtual London Healthcare Conference
Read more -
Ryvu Therapeutics at BIO-Europe 2020
Read more -
Ryvu Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting (SITC 2020)
Read more -
First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more -
Ryvu Therapeutics Reports 2020 Half-Year Financial Results
Read more -
Ryvu Therapeutics to present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Read more -
Ryvu Therapeutics raised over USD 36 million from its share issue
Read more -
The share issue price in Ryvu Therapeutics public offering set at PLN 60
Read more -
Ryvu Therapeutics shareholders have approved a new share issue. Book-building starts today.
Read more -
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
Read more -
Ryvu Therapeutics signs a grant agreement for the development of targeted immuno-oncology therapy
Read more -
NodThera, Ryvu spin-off company, secures £44.5million ($54.5million) Series B Financing
Read more -
Ryvu Therapeutics has completed the construction of the R&D Center for Innovative Drugs
Read more -
Ryvu Therapeutics at BIO Digital 2020
Read more -
Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Read more -
Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II
Read more -
Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress
Read more -
Galapagos and Ryvu announce research collaboration
Read more -
Ryvu Therapeutics Reports Annual 2019 Financial Results
Read more -
Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference
Read more -
Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia
Read more -
Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read more -
Ryvu Therapeutics at BIO-Europe Spring 2020
Read more -
Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference
Read more -
Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept
Read more -
Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors
Read more -
Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules
Read more
-
Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read more -
Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read more -
Ryvu Therapeutics to Present at BIO-Europe 2019
Read more -
Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read more -
Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read more -
Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read more -
Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read more -
Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read more -
Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read more -
Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read more -
Selvita to Present at Upcoming Conferences in September
Read more -
Selvita announces availability of abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for presentation at 2019 ASCO Annual Meeting and 24th EHA Congress
Read more -
Selvita to Present at the UBS 2019 Global Healthcare Conference in New York
Read more -
Poster regarding Phase 1/2 study of SEL24/MEN1703 accepted for the ASCO 2019 Annual Meeting
Read more -
Selvita to present at the 2019 HCW Global Life Sciences Conference in London
Read more -
Selvita to Separate Oncology Therapeutics and Contract Research Business Units into Two Global Companies
Read more -
Selvita Announces U.S. FDA Acceptance of Investigational New Drug Application to Commence Clinical Development of SEL120 in the Treatment of Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Read more -
Selvita to Present Data from Multiple Oncology Programs at AACR 2019 Annual Meeting
Read more -
Selvita to Present at Biotech Showcase 2019 in San Francisco
Read more -
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more
-
Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting
Read more -
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Read more -
Selvita to present new data from its oncology programs at the upcoming SITC 2018
Read more -
Selvita presents new data from SEL120 program during Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice
Read more -
Selvita presents at the 25th Annual BioCentury NewsMakers in the Biotech Industry
Read more -
Selvita to present new data from its oncology programs at the 6th Annual Immuno-Oncology Summit
Read more -
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results on SEL24 potential in Chronic Lymphocytic Leukemia
Read more -
Selvita publishes research results on SEL24 in Oncotarget
Read more -
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2018
Read more -
Selvita Announces Successful Completion of $41 M Book Building
Read more
-
FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read more -
Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read more -
Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more -
Selvita and Menarini present together at the European Business Development Conference
Read more -
Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read more -
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read more -
Selvita presents at 18th Drug Discovery Summit in Berlin
Read more -
Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read more -
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read more -
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read more -
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017
Read more -
Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry
Read more
-
Selvita to present at Biotech Showcase 2017 in San Francisco
Read more -
Selvita presents posters at 2016 EORTC-NCI-AACR Symposium
Read more -
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more -
FDA has accepted Selvita’s IND application for the SEL24 Phase I/II clinical trial in AML
Read more -
Epidarex Capital Creates Nodthera Limite
Read more -
Selvita epigenetic project is the first Polish drug target program selected by EU Lead Factory
Read more -
Selvita will present at the 18th Annual BIO CEO & Investor Conference 2016
Read more
-
Selvita wins the European Rising Star Award
Read more -
The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition
Read more -
Merck and Selvita Announce Drug Discovery Collaboration
Read more -
Selvita launches new company – bioinformatics and personalized medicine focused Ardigen
Read more -
H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration
Read more -
Selvita receives the Economic Award of the President of Poland
Read more -
Selvita initiates IND-enabling Studies for its first-in-class PIM/FLT3 inhibitor
Read more
-
Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence
Read more -
Selvita and H3 Biomedicine will present at the Drug Discovery USA Congress 2014
Read more -
New data from Selvita’s SEL24 will be presented by Institute of Hematology and Transfusion Medicine (IHT) at the ASH Meeting on Lymphoma Biology 2014
Read more